AU2021339010A1 - Antitumoral ascorbic acid esters - Google Patents

Antitumoral ascorbic acid esters Download PDF

Info

Publication number
AU2021339010A1
AU2021339010A1 AU2021339010A AU2021339010A AU2021339010A1 AU 2021339010 A1 AU2021339010 A1 AU 2021339010A1 AU 2021339010 A AU2021339010 A AU 2021339010A AU 2021339010 A AU2021339010 A AU 2021339010A AU 2021339010 A1 AU2021339010 A1 AU 2021339010A1
Authority
AU
Australia
Prior art keywords
compound
esi
mmol
ethylacetate
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021339010A
Other languages
English (en)
Inventor
Yagamare Fall Diop
Fatima Garrido Fernandez
María Generosa De Los Ángeles Gómez Pacios
Guido Kurz
Teresa Royo Bargués
María Rúbies Royo
Hugo Santalla Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suigeneris Farmacosmetics SL
Original Assignee
Suigeneris Farmacosmetics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suigeneris Farmacosmetics S L filed Critical Suigeneris Farmacosmetics S L
Publication of AU2021339010A1 publication Critical patent/AU2021339010A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021339010A 2020-09-14 2021-09-13 Antitumoral ascorbic acid esters Pending AU2021339010A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382804.1A EP3967684A1 (en) 2020-09-14 2020-09-14 Antitumoral ascorbic acid esters
EP20382804.1 2020-09-14
PCT/EP2021/075104 WO2022053679A1 (en) 2020-09-14 2021-09-13 Antitumoral ascorbic acid esters

Publications (1)

Publication Number Publication Date
AU2021339010A1 true AU2021339010A1 (en) 2023-03-23

Family

ID=72709280

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021339010A Pending AU2021339010A1 (en) 2020-09-14 2021-09-13 Antitumoral ascorbic acid esters

Country Status (10)

Country Link
US (1) US20230278974A1 (https=)
EP (2) EP3967684A1 (https=)
JP (1) JP7805651B2 (https=)
KR (1) KR20230088718A (https=)
CN (1) CN116724028B (https=)
AU (1) AU2021339010A1 (https=)
CA (1) CA3191119A1 (https=)
ES (1) ES3006988T3 (https=)
MX (1) MX2023002970A (https=)
WO (1) WO2022053679A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4676461A1 (en) * 2023-03-09 2026-01-14 Mastery Biotech Co., Ltd. Conjugate compound comprising 13-cis-retinoic acid and ascorbic acid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2831395B2 (ja) * 1989-09-12 1998-12-02 ハリマ化成株式会社 アスコルビン酸エステル
JP3781877B2 (ja) * 1997-10-03 2006-05-31 株式会社ムック アスコルビン酸誘導体またはその塩、および医薬
CN101550119B (zh) 2009-05-11 2012-05-30 无锡宏瑞生物医药科技有限公司 芳基(乙)丙酸抗坏血酸酯,其制备方法及含有它们的药物
JP2016104708A (ja) 2014-12-01 2016-06-09 参天製薬株式会社 アスコルビン酸誘導体を含有する非水性注射剤及びデポ形成方法
JP6588764B2 (ja) 2015-01-26 2019-10-09 章博 田井 抗腫瘍剤
CN106139151A (zh) * 2016-04-29 2016-11-23 陈西敬 抗坏血酸棕榈酰酯与抗肿瘤药物协同作用的药物组合物
CA3031979A1 (en) * 2016-08-01 2018-02-08 IC-MedTech Corp. Ascorbic acid, quinone compound, and sodium glucose cotransporter inhibitor for treating cancer

Also Published As

Publication number Publication date
CA3191119A1 (en) 2022-03-17
KR20230088718A (ko) 2023-06-20
ES3006988T3 (en) 2025-03-19
JP7805651B2 (ja) 2026-01-26
EP4211123C0 (en) 2024-11-06
JP2023541840A (ja) 2023-10-04
CN116724028B (zh) 2025-07-08
WO2022053679A1 (en) 2022-03-17
US20230278974A1 (en) 2023-09-07
EP4211123A1 (en) 2023-07-19
CN116724028A (zh) 2023-09-08
EP4211123B1 (en) 2024-11-06
EP3967684A1 (en) 2022-03-16
MX2023002970A (es) 2023-05-15

Similar Documents

Publication Publication Date Title
US11485726B2 (en) Compound for inhibiting and degrading tyrosine protein kinase ALK
EP4570795A1 (en) Heterocyclic compound for inducing degradation of g12v mutant kras protein
JP6031122B2 (ja) 抗微生物療法のための三環式ホウ素化合物
US7399754B2 (en) N2-quinoline or isoquinoline substituted purine derivatives
CN112804995B (zh) 隐杯伞素类似物、其应用及其合成方法
WO2010024356A1 (ja) ナフチリジン－ｎ－オキシドを有する新規ヒドロキサム酸誘導体
WO2018133661A1 (zh) 一种新的硼酸衍生物及其药物组合物
CN102010421A (zh) 青蒿素类衍生物及其应用
US9738613B2 (en) Substituted 1,2,3-triazoles as antitumor agents
EP4211123B1 (en) Antitumoral ascorbic acid esters
CN114181161B (zh) (2-((取代氧基)苯基)氨基)嘧啶-4-基)氨基苯甲酰衍生物及其制备方法与应用
WO2011082519A1 (zh) 格尔德霉素衍生物及其制备方法和用途
EP1902054B1 (fr) Derives de pyrido[2,3-d]pyrimidine, leur preparation, leur application en therapeutique
EP3978473A1 (en) Compound containing an indoleacetic acid core structure and use thereof
CN114380864A (zh) 一种双氢青蒿素衍生物、制备方法、药物组合物和其在制备抗肿瘤药物中的应用
CN104327097A (zh) 雷帕霉素的三氮唑衍生物和用途
WO2012025054A1 (zh) 小檗胺的二酰亚胺化衍生物、其制备方法和应用
US20150045404A1 (en) Schweinfurthin analogues
CN106243130A (zh) 3,6‑二芳基‑[1,2,4]三氮唑并[3,4‑b][1,3,4]噻二嗪类化合物及其用途
CN114181159B (zh) 含2,4,5-三取代嘧啶酰肼衍生物及其制备方法与应用
CN103450164B (zh) 格尔德霉素衍生物及其制备方法和用途
US20240101585A1 (en) Heteroaromatic phosphonium salts and their use treating cancer
WO2022040788A1 (en) Open-ring and lactone derivatives of unsaturated trihydroxy c-18 fatty acids and pharmaceutical compositions thereof having anti-cancer activity
CN117567345A (zh) 一种用于抑制卵巢肿瘤化合物的制备方法及应用
HK40070404A (en) Compound containing an indoleacetic acid core structure and use thereof